Protagonist Therapeutics, Inc (NASDAQ: PTGX)

Protagonist Therapeutics, Inc., a biopharmaceutical company listed under the symbol PTGX, operates in the healthcare sector, specifically in the development of peptide-based new chemical entities for the treatment of hematology and blood disorders, as well as inflammatory and immunomodulatory diseases.

Protagonist Therapeutics' primary business activities revolve around the discovery, development, and commercialization of innovative therapeutic solutions. The company's operations span across various countries, with a significant focus on the United States. Their research and development efforts are geared towards addressing unmet medical needs in the aforementioned therapeutic areas.

The company generates revenue through the development and commercialization of its primary products and services. Its most advanced clinical asset, rusfertide, is an injectable hepcidin mimetic being developed for the treatment of polycythemia vera (PV) and other blood disorders. Another key product candidate is JNJ-2113, an orally delivered interleukin-23 receptor (IL-23R) antagonist, which is being developed for the treatment of inflammatory bowel disease (IBD) and other inflammatory conditions.

Within the industry, Protagonist Therapeutics competes with several key players. However, the company's competitive advantage lies in its discovery platform, which enables the design and development of novel, structurally constrained peptides. This unique platform sets the company apart, providing it with a strong position in the industry.

Protagonist Therapeutics' customer base primarily consists of patients with PV and other blood disorders, as well as patients with IBD and other inflammatory conditions. The company is committed to establishing relationships with healthcare providers and payors to ensure access to its products.

Among the brand names and trade names of its products and services, rusfertide and JNJ-2113 stand out. These are the company's most advanced clinical assets, with promising results in clinical trials.

In the field of psoriasis, there is an urgent need for safe and effective oral therapies. The development of JNJ-2113, an orally delivered IL-23R antagonist, is a significant step towards addressing this need. The IL-23/IL-17 axis is a key pathway driving psoriatic inflammation, and the development of targeted therapies that inhibit this axis has revolutionized the treatment of moderate-to-severe psoriasis.